Post-Conference Perspectives: Peripheral T-Cell Lymphoma

Post-Conference Perspectives: Peripheral T-Cell Lymphoma

Episodes

Specialty:

All

Year:

All

EP. 1: Peripheral T-Cell Lymphoma Classifications and CD30 Testing

January 28th 2019

EP. 2: T-Cell Lymphoma Differential Diagnosis and CD30 Treatment

January 28th 2019

EP. 3: Brentuximab Vedotin Overview and Treatment Advice

January 28th 2019

EP. 4: The ECHELON-2 Trial Presented at ASH 2018

January 28th 2019

EP. 5: PTCL Community Treatment and Future Advancements

January 28th 2019

EP. 6: An Overview of Peripheral T-Cell Lymphoma

January 28th 2019

EP. 7: Treating Patients With CD30-Positive PTCL

January 28th 2019

EP. 8: The Impact of Brentuximab Vedotin as PTCL Treatment

January 28th 2019

EP. 9: PTCL Treatment in the Community Setting

January 28th 2019

EP. 10: The Current Unmet Needs in PTCL Treatment and Prospects

January 28th 2019

Trending on OncLive

Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC

Adjuvant Intismeran Autogene Plus Pembrolizumab Improves RFS and DMFS in Melanoma

DASL-HiCaP: Darolutamide Plus ADT and Radiation Therapy Improves MFS in Very High-Risk Localized Prostate Cancer

DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC

Atirmociclib Plus Fulvestrant Improves PFS in HR+/HER2– Advanced Breast Cancer